Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company developing new treatments for liver diseases and viral infections. The company focuses on chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections (such as SARS‑CoV‑2, SARS‑CoV, MERS‑CoV, and related infections). Aligos's drug candidate pipeline includes pevifoscorvir sodium (previously ALG-000184) for chronic HBV infection, ALG‑055009 for MASH and obesity, and ALG‑097558 for coronavirus infections, along with preclinical programs. Pevifoscorvir sodium is a Capsid Assembly Modulator (CAM‑E) for chronic HBV infection. Preclinical testing showed enhanced pharmacologic properties compared to competitor CAM‑E drugs and greater HBV DNA suppression than standard nucleos(t)ide analogs (NAs). A multi‑part Phase 1 clinical trial, spanning up to 96 weeks, demonstrated multi-log 10 reductions in viral antigens. ALG‑055009 is a thyroid hormone receptor beta (THR‑β) agonist for MASH and obesity. Data to date suggest enhanced pharmacologic properties compared to competitor THR‑β agonists. Phase 2a topline data showed that ALG‑055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12, measured by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF), in subjects with presumed MASH. Recent nonclinical data indicate synergistic fat mass loss when combined with incretin receptor agonists in diet-induced obese (DIO) mice. ALG‑097558 is a small molecule coronavirus 3CL protease inhibitor (PI). It is at least 3‑fold more potent in cell‑based assays of coronavirus infection than other approved CoV PIs. Based on Phase 1 clinical studies, the company believes it can be dosed twice daily without requiring ritonavir co-dosing.